Autolus: Funding, Investors & Team (Oct 2026)
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
Autolus has raised $150M across 1 funding round on record, the most recent an undisclosed round of $150M announced in Dec 2022.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Autolus Company Profile and Key Stats
Latest funding round on record: Dec 2022.
Autolus Funding Rounds
Autolus Founders and Leadership Team
No contact details are on record for this team yet.
Autolus Funding Compared to Other Biotechnology Startups
Autolus' latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Autolus in Biotechnology and London
Companies Similar to Autolus
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
Autolus Funding FAQs
What does Autolus do?
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
How much funding has Autolus raised?
Autolus has raised $150M across 1 round on record. The most recent is an undisclosed round of $150M announced in Dec 2022.
When did Autolus last raise funding?
Autolus' most recent funding round on record is an undisclosed round of $150M, announced in Dec 2022.
Who founded Autolus?
FundedIQ lists Martin Pule (Founder) at Autolus.
Where is Autolus headquartered?
Autolus is based in London, England, United Kingdom.
How many employees does Autolus have?
Autolus is in the 251-500 employee band.
How does Autolus' funding compare to other Biotechnology startups?
Autolus' latest round of $150M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Autolus Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Autolus is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.